|
||
© The Rockefeller University Press,
0021-9525/2002/4/327 $5.00
The Journal of Cell Biology, Volume 157, Number 2, April 15, 2002 327-336
Article |
Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes
: implications for Pelizaeus-Merzbacher disease
2 Max Planck Institute for Developmental Biology, 72076 Tübingen, Germany
3 Department of Neurogenetics, Max Planck Institute for Experimental Medicine, 37075 Göttingen, Germany
4 Department of Neurobiology, University of Heidelberg, 69120 Heidelberg, Germany
Address correspondence to Mikael Simons, Department of Neurology, University of Tübingen, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany. Tel.: 49-707-160-1329. Fax: 49-707-129-5260. E-mail: mika.simons{at}uni-tuebingen.de
| Abstract |
|---|
|
|
|---|
Duplications and overexpression of the proteolipid protein (PLP) gene are known to cause the dysmyelinating disorder Pelizaeus-Merzbacher disease (PMD). To understand the cellular response to overexpressed PLP in PMD, we have overexpressed PLP in BHK cells and primary cultures of oligodendrocytes with the Semliki Forest virus expression system. Overexpressed PLP was routed to late endosomes/lysosomes and caused a sequestration of cholesterol in these compartments. Similar results were seen in transgenic mice overexpressing PLP. With time, the endosomal/lysosomal accumulation of cholesterol and PLP led to an increase in the amount of detergent-insoluble cellular cholesterol and PLP. In addition, two fluorescent sphingolipids, BODIPYlactosylceramide and galactosylceramide, which under normal conditions are sorted to the Golgi apparatus, were missorted to perinuclear structures. This was also the case for the lipid raft marker glucosylphosphatidylinositolyellow fluorescence protein, which under normal steady-state conditions is localized on the plasma membrane and to the Golgi complex. Taken together, we show that overexpression of PLP leads to the formation of endosomal/lysosomal accumulations of cholesterol and PLP, accompanied by the mistrafficking of raft components. We propose that these accumulations perturb the process of myelination and impair the viability of oligodendrocytes.
Key Words: proteolipid protein; cholesterol; myelin; rafts; Pelizaeus-Merzbacher disease
| Introduction |
|---|
|
|
|---|
50% hydrophobic amino acids. The protein is covalently attached to several acyl chains and interacts with cholesterol (Weimbs and Stoffel, 1992; Simons et al., 2000). The association of PLP with cholesterol and galactosylceramide-enriched membrane domains, so-called myelin rafts, during biosynthetic transport in primary cultures of oligodendrocytes may be critical for the correct sorting of PLP and the assembly of myelin in the CNS (Simons et al., 2000). Lipid rafts are cholesterol- and sphingolipid-rich membrane domains that form platforms for specific proteins and regulate, for example, intracellular membrane transport and cell signaling (Simons and Ikonen, 1997; Brown and London, 2000). We have previously proposed that PLP-containing myelin rafts represent specialized forms of lipid rafts, characterized by their unique subset of sphingolipids, galactosylceramide and sulfatide (Simons et al., 2000). Whereas cholesterolsphingolipid rafts have been isolated based on their insolubility in the detergents Triton X-100 and CHAPS, myelin rafts containing PLP can only be recovered from the CHAPS-insoluble membrane fraction (Pereyra et al., 1988; van der Haar et al., 1998; Brown and Rose, 1992; Kim et al., 1995; Krämer et al., 1997; Simons et al., 2000). Although the exact role of PLP in myelin remains undefined, it is known to be associated with human disease. In humans, a variety of mutations, including missense mutations, deletions, and duplications, of the PLP gene are known to cause the dysmyelinating disorders Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia (Garbern et al., 1999). Gene duplications of the human PLP locus are responsible for the majority of cases of PMD and lead to enhanced expression of the PLP protein (Hodes and Dlouhy, 1996). The cellular mechanism of dysmyelination caused by mutations of the PLP gene has only been studied in detail for the missense mutations (Gow and Lazzarini, 1996). This work has shown that most point mutations lead to accumulation of the protein in the ER, presumably due to its misfolding (Gow and Lazzarini, 1996; Gow et al., 1998). Transgenic mice harboring additional copies of the wild-type PLP gene have demonstrated a premature arrest of myelination and, at higher PLP gene dosage, abnormal oligodendrocyte cell death (Kagawa et al., 1994; Readhead et al., 1994). However, the molecular pathology of PLP overexpression has remained obscure. In the present study, we have studied the overexpression of PLP in BHK cells, cultured oligodendrocytes, and transgenic mice. We demonstrate the abnormal accumulation of PLP, cholesterol, and other raft components in the late endosomal/lysosomal compartment and suggest that the mistrafficking of these myelin components are involved in the pathology associated with PLP overexpression.
| Results |
|---|
|
|
|---|
14 h), was mainly found in the Golgi region and at the plasma membrane (unpublished data). At later time points after transfection, PLP accumulated in the endosomallysosomal system, as shown by colocalization with the fluid-phase marker rhodaminedextran (Fig. 1 a). Cells were labeled with different markers of the endosomallysosomal system to determine the exact subcellular localization of PLP. We found no overlap between PLPmyc and early endosomal antigen 1 (EEA1), a marker of early endosomes (Fig. 1 b), or between PLP and transferrinrhodamine, a marker of recycling endosomes (Fig. 1 c). In contrast, PLP colocalized with lysobisphosphatidic acid (LBPA), which localizes to late endosomes (Fig. 1 d). The presence of PLP within late endosomes/lysosomes is consistent with earlier reports (Gow et al., 1994; Sinoway et al., 1994; Kalway et al., 1997; Krämer et al., 2001).
|
|
40% of normal levels (Keller and Simons, 1998), before detergent extraction. Depletion of cellular cholesterol caused a shift of a significant amount of PLP toward fractions of higher density (Fig. 3 b). To rule out the possibility that raft association at late postinfection times was due to an artifact caused by the viral expression system, we determined the raft association of the viral spike protein E2, 5 and 20 h after infection. In contrast to the observation with PLP, the amount of E2 recovered from the CHAPS-insoluble membrane fraction did not increase 20 h after infection, as compared with 5 h (Fig. 3 c).
|
Effect of endosomal accumulation of cholesterol and PLP on cellular cholesterol homeostasis
The redistribution of cellular cholesterol to the degradative compartment of the endosomal system may have important consequences for cellular cholesterol homeostasis. We therefore analyzed the effect of PLP expression on total cholesterol levels, cholesterol efflux, and de novo cholesterol synthesis in BHK cells. We found that total cholesterol levels were not changed (unpublished data). Cholesterol biosynthesis was analyzed by incubating cells infected with SFV-PLPmyc or SFV-GFP 14 h after infection for 4 h with [14C]acetate. After a 2-h chase, [14C]cholesterol levels were quantified from TLC plates. We did not observe a difference between cells infected with SFV-PLPmyc and cells infected with SFV-GFP (unpublished data). To evaluate the cholesterol efflux from the plasma membrane, we labeled cells for 24 h with [14C]cholesterol in lipoprotein-deficient medium, infected the cells with SFV-PLPmyc or SFV-GFP for 20 h in the absence of label, and extracted with mßCd. We used a 30-min incubation with 10 mM mßCd on ice, which extracted 26.8 ± 3% (n = 9) of the cholesterol in uninfected cells. 27.1 ± 2% (n = 3) of the cholesterol was removed from cells that had been infected with SFV-GFP. In cells expressing PLP, a small reduction in cholesterol efflux was observed (20.2% ± 2.2%, n = 9). Because cholesterol is redistributed to late endosomes/lysosomes while total cholesterol levels remain unchanged, there may be less cholesterol available for extracellular acceptors at the plasma membrane in this latter case.
Accumulation of PLP and cholesterol in the endosomal system impairs the trafficking of raft components
Having shown that PLP induces redistribution of cellular cholesterol to late endosomes/lysosomes, we tested whether this affects the sorting of other (raft) lipids. To monitor the trafficking of sphingolipids, we added BODIPY-labeled lipids to the cells. It has been shown previously that BODIPYlactosylceramide or galactosylceramide are taken up by cells and transferred to the Golgi apparatus (Puri et al., 1999). In several lysosomal storage diseases, however, these lipids are rerouted to the late endosomes/lysosomes (Puri et al., 1999). We therefore analyzed how these lipids are transported in cells that express PLP. BHK cells were infected with SFV-PLPmyc, and 1620 h after infection, BODIPY-labeled lipids were added to the cells as BSA complexes for 1 h at 37°C, and internalization was allowed to proceed for 90 min. After "back exchange" (see Materials and methods) of the lipids at 12°C, the distribution of the labeled lipid was monitored. As previously shown, both BODIPYgalactosylceramide and lactosylceramide distributed to the Golgi region in uninfected cells (Fig. 4, a and c). In cells infected with SFV-PLPmyc, however, both lipids were found in a perinuclear location in enlarged vesicles within the cell (Fig. 4, b and d). These results demonstrate that expression of PLP in BHK cells alters the trafficking of both cholesterol and fluorescent sphingolipids. One consequence of this might be an altered trafficking of lipid rafts. As a marker for lipid rafts, we used yellow fluorescence protein (YFP) fused to a glucosylphosphatidylinositol (GPI) anchor (GPIYFP; Keller et al., 2001). In BHK cells, GPIYFP is mainly found at the plasma membrane (Fig. 5 a). When GPIYFP and PLP were coexpressed in BHK cells, the localization of GPIYFP was completely altered and both proteins showed a complete colocalization (Fig. 5 c). A similar redistribution of GPIYFP was observed when GPIYFP-expressing cells were treated with the drug U18666A, a hydrophobic amine, which induces late endosomal/lysosomal cholesterol accumulation by inhibition of cholesterol mobilization (Liscum, 2000; Fig. 5 b). Taken together, we conclude that the trapping of cholesterol by overexpressed PLP in the endosomallysosomal system induces the missorting of raft membrane components.
|
|
|
|
4050%, n = 3) into myelin rafts in oligodendroglial precursor cells (unpublished data). These data rule out the possibility that the viral expression system or the myc tag interferes with raft incorporation and suggest that raft association is reduced in primary cultures of oligodendrocytes because the protein is overexpressed.
|
PLP-overexpressing mice accumulate PLP and cholesterol in late endosomes/lysosomes
Transgenic mice with increased dosage of the PLP gene have been useful models for PMD (Kagawa et al., 1994; Readhead et al., 1994). These mice develop a dys- and demyelinating disease, the severity of which is related to the level of PLP overexpression. Immunocytochemistry with antibodies against PLP/DM20 has shown that PLP/DM20 distributes differently in transgenic mice compared with wild type (Gow et al., 1998). PLP/DM20 is found in myelin tracts that can be followed over a long distance through brain sections in wild-type mice, whereas PLP/DM20 localizes to short and swollen myelin segments in transgenic mice. Furthermore, PLP/DM20 was found to accumulate at a perinuclear location in many oligodendrocytes of the transgenic animal (Macklin et al., 1995; Gow et al., 1998). The subcellular compartment of these perinuclear accumulations has not yet been determined. To analyze whether PLP/DM20 accumulates in late endosomes/lysosomes in PLP-overexpressing oligodendrocytes, we performed immunolocalization of PLP in situ. Sagittal sections of the brain of 3-wk-old homozygous PLP-overexpressing mice (line no. 66 in Readhead et al., 1994) were stained with antibodies against PLP/DM20 and LAMP-1. We found that PLP/DM20 accumulated in the perinuclear region and colocalized with LAMP-1 (Fig. 9 a). Quantitative analysis of the sections indicated that colocalization of PLP and LAMP-1 was increased >10-fold in PLP-overexpressing mice (line no. 66) compared with age-matched wild-type control mice. When tissue sections were labeled with filipin, we found that a significant amount (
40%) of LAMP-1 and PLP-positive structures were also labeled with filipin (Fig. 9, b and c). These results strongly suggest that PLP overexpression in vivo also causes the proteins to accumulate in late endosomes/lysosomes; thus, our in vitro results are also relevant for the pathogenesis of PMD.
|
| Discussion |
|---|
|
|
|---|
If PLP is able to form and associate with rafts in the endosomallysosomal system of BHK cells, why is the protein not incorporated into rafts in the Golgi complex in the first place? The affinity of PLP to BHK rafts may be low, and therefore PLP might not be incorporated into rafts during the biosynthetic transport. Only after accumulation of PLP in late endosomes and cumulative sequestration of cholesterol and other raft lipids is association to rafts possible. It could be that the accumulation leads to clustering of raft lipids, and this in turn increases PLP association with rafts. For example, the NPC protein is detergent soluble in normal fibroblasts, but in NPC cells, when lipid-rafts accumulate in late endosomes/lysosomes, it becomes increasingly detergent insoluble (Lusa et al., 2001). Likewise, the clustering of rafts might also be involved in the activation of lymphoid cells and is known to enhance the affinity of the T cell receptor to rafts (Viola, 2001). More work will be required to elucidate the interaction of PLP with the different raft lipids and to define how these interactions influence the trafficking behavior of PLP.
What is the significance of this finding for the pathogenesis of PMD? There are now several lines of evidence that PMD is a result of toxic "gain of function" of PLP, rather than a loss of functional protein. For example, PLP knockout mice have a remarkably mild phenotype (Klugmann et al., 1997), whereas missense mutations or increased gene dosage of PLP lead to severe forms of PMD (Garbern et al., 1999). For the missense mutations, it has been shown that the underlying pathogenic mechanism is the accumulation of misfolded protein in the ER (Gow and Lazzarini, 1996). Misfolded PLP is harmful to the cell and provokes an "unfolded protein response," which leads to subsequent cell death by apoptosis (Gow et al., 1998). However, for the majority of patients with PMD due to gene duplication followed by an increased gene dosage of PLP, the molecular nature of the toxic "gain of function" has remained obscure. As a disease mechanism, we and others have proposed that PLP overexpression results in an arrest of oligodendrocyte and myelin development (Kagawa et al., 1994; Readhead et al., 1994). However, these studies did not show whether arrested myelin development is a direct effect of PLP expression or possibly a secondary effect due to abnormal accumulation of PLP. It is unlikely that overexpression of PLP leads to accumulation of misfolded protein in the ER, as observed for the missense mutations. When the SFV expression system was used, PLP was not retained in the ER of BHK cells or oligodendrocytes. Instead, we found that overexpression of PLP leads to the formation of detergent-insoluble accumulation of cholesterol and PLP within late endosomes/lysosomes. Because these raft aggregates seem to disturb raft membrane trafficking, it is possible that they also impair the process of myelination. Other myelin lipids may be trapped along with PLP in late endosomes/lysosomes. The capacity of late endosomes/lysosomes to recycle and/or degrade myelin membrane might also be disturbed and induce or accelerate the disease process. Furthermore, important signaling molecules that are required to initiate myelination, such as fyn, are found in rafts in oligodendrocytes (Krämer et al., 1997). Myelination is significantly reduced in fyn-deficient transgenic mice (Umemori et al., 1994; Sperber et al., 2001), and morphological differentiation of oligodendrocytes requires activation of fyn tyrosine kinase (Osterhout et al., 1999). It is tempting to speculate that the impairment of raft membrane trafficking induced by overexpression of PLP disturbs fyn signaling.
Interestingly, increased dosage of the peripheral myelin protein 22 is involved in diseases of peripheral myelin (Charcot-Marie tooth disease type 1 and hereditary neuropathy with liability to pressure palsies; Suter and Snipes, 1995). Myelinating cells may be particularly sensitive to an imbalance in the synthesis and turnover of myelin components due to their high rate of myelin synthesis (Pfeiffer et al., 1993). It is likely that oligodendrocytes trigger a death program early in the disease process. Indeed, mouse models of PMD that carry extra copies of the PLP gene show that oligodendrocytes die prematurely, i.e., as early as a few weeks after birth depending on the levels of expression of the PLP transcript (Kagawa et al., 1994; Readhead et al., 1994; Inoue et al., 1996). Furthermore, we have observed that the viability of immortalized oligodendroglial precursor cells is reduced by 24% in cells where PLP was expressed for 20 h with the SFV expression system, compared with cells that expressed MOG (unpublished data). An important issue for future studies is the mechanism of induction and execution of cell death in PLP-overexpressing oligodendrocytes.
| Materials and methods |
|---|
|
|
|---|
Cell culture and transfection
Primary cultures of oligodendrocytes were prepared and maintained as described previously (Simons et al., 2000). The immortalized oligodendroglial precursor cell line (Oli-neu) was cultured as described previously (Jung et al., 1995). BHK-21 cells were cultured in G-MEM (GIBCO BRL) containing 5% FCS and supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), and 2 mM glutamine (all from GIBCO BRL). Transfection of BHK cells was performed with FuGENE transfection reagents (Roche Molecular Biochemicals) according to the manufacturer's protocol.
Preparation of detergent-insoluble membrane fractions
Detergent extraction was performed as described by Simons et al. (2000) and Brown and Rose (1992). Primary oligodendrocytes or BHK cells cultured in a 5-cm dish were washed in PBS, scraped into 300 µl of 50 mM Tris-HCl, pH 7.4, 5 mM EDTA (TE), supplemented with protease inhibitors, and extracted for 30 min by adding CHAPS (20 mM final concentration). For lipid analysis, cells were grown in 10-cm dishes, washed, and scraped in PBS. The cell pellet was extracted with 350 µl of 20 mM CHAPS in TE buffer. The samples were either floated in an Optiprep step gradient (40, 30, 0% Optiprep) as previously described (Simons et al., 2000) or centrifuged at 14,000 g for 30 min at 4°C and processed as described by Brown and Rose (1992). The resulting fractions were processed for SDS-PAGE, followed by immunoblotting, or for TLC as described.
DNA constructs, preparation of recombinant SFV, and infection of cells
For preparation of recombinant SFV, we followed the protocol of Liljeström and Garoff (1991). A c-myc epitope (EQKLISEEDL) was introduced at the COOH terminus of PLP and subcloned into the pCMV vector. The PLPmyc, PLP, MOG, and GFP cDNA were cloned into the SmaI restriction site of pSFV1. pSFV1 was linearized using Nru1, pSFV-helper 1 using Spe1, and runoff transcription was performed with SP6 RNA polymerase. The transcription mix was cotransfected with the helpertranscription mix into BHK cells using electroporation. The culture supernatant was collected after a 24-h incubation (5% CO2, 37°C). The virus-containing supernatant was titrated on BHK cells. For infection, cells were incubated for 1 h with recombinant SFV diluted in conditioned maintenance medium (5% CO2, 37°C). The virus was replaced by maintenance medium and the infection continued for 520 h.
Lipid analysis
To analyze de novo cholesterol synthesis, BHK cells grown in 5-cm dishes were infected with SFV-PLPmyc or SFV-GFP or were left uninfected. 16 h after infection, cells were labeled with [14C]acetate (50 µCi/ml) for 4 h in G-MEM containing 5% lipoprotein-deficient FCS and chased for 2 h in normal medium. Cells were scraped into ice-cold PBS, harvested by centrifugation, and resuspended in 2% NaCl. To analyze total cholesterol levels or CHAPS insolubility of cholesterol, cells were infected for 20 h or left uninfected and processed as described above. Lipids were extracted, separated, and quantified as described by Simons et al. (2000). Cholesterol efflux was performed essentially as detailed by Lusa et al. (2001). BHK cells were labeled with 0.5 µCi/ml [14C]cholesterol in G-MEM containing 5% lipoprotein-deficient FCS for 24 h, infected or not, and incubated for 20 h in the absence of label in normal maintenance medium. Efflux to 10 mM mßCd was performed on ice for 30 min in serum-free medium. Medium was removed, cells were harvested in 2% NP-40, 0.2% SDS in TE, and the radioactivity was determined in both fractions by liquid scintillation counting. BODIPYgalactosylceramide and lactosylceramide were added to cells as a BSA complex, and cells were cultured for 45 min at 37°C in culture medium (Puri et al., 1999). They were then washed and further incubated for 1 h at 37°C in culture medium. Fluorescent lipid present at the plasma membrane was then removed by washing six times with 3% defatted BSA at 12°C ("back exchange") (Martin and Pagano 1994).
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde in PBS, pH 7.4, permeabilized with 0.1% Triton X-100 at room temperature (RT) or on ice for 30 s for filipin stainings, and blocked in 2% FCS and 0.2% gelatin in PBS. The cells were incubated in the presence of primary antibody for 1 h at RT, washed three times for 5 min with PBS, incubated with the appropriate secondary antibodies, washed again, and mounted. For filipin labeling, cells were incubated for 20 min at RT with filipin diluted in PBS (0.5 mg/ml), washed two times for 5 min in PBS, and mounted. Fluorescent images were obtained using Axiophot (ZEISS) or a confocal microscope (TCS confocal system; Leica). For immunocytochemistry on brain sections, mice were anesthetized and fixed by vascular perfusion with 4% paraformaldehyde in 0.1 M sodium phosphate, pH 7.2. Brains were dissected and infiltrated with 20% sucrose in phosphate buffer at 4°C before cryostat sectioning. Frozen sections (1020 µm) were mounted, permeabilized for 10 min with methanol (-20°C), and labeled with primary antibody (overnight at RT) and the respective secondary antibody (4 h at RT). For filipin labeling, sections were incubated in quenching solution (1.5 mg/ml glycine, 1% BSA, 0.02% saponinPBS) at RT for 30 min. This was followed by incubating sections with filipin (0.005 mg/ml) for 10 min in the dark while shaking. Cells that showed colocalization of PLP and LAMP-1 were counted from 50 random fields from four different sagittal sections of wild-type or transgenic mice. 119 cells were counted from the sections of the transgenic animal, and 8 cells were counted from the sections of the wild-type animal.
| Footnotes |
|---|
| Acknowledgments |
|---|
This work was supported by Fortüne (University of Tübingen) and by SFB446.
Submitted: 29 October 2001
Revised: 12 March 2002
Accepted: 14 March 2002
| References |
|---|
|
|
|---|
Brown, D.A., and E. London. 2000. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J. Biol. Chem. 275:1722117224.
Brown, D.A., and J.K. Rose. 1992. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical surface. Cell. 68:533544.[CrossRef][Medline]
Brown, M.S., and J.L. Goldstein. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science. 232:3447.
Brotherus, J., and O. Renkonen. 1977. Subcellular distribution of lipids in cultured BHK cells: evidence for the enrichment of lysobisphosphatic acid and neutral lipids in lysosomes. J. Lipid Res. 18:191202.[Abstract]
Gagescu, R., N. Demaurex, R.G. Parton, W. Hunzinger, L.A. Huber, and J. Gruenberg. 2000. The recycling endosome of Madin-Darby canine kidney cells is a mildly acidic compartment rich in raft compartments. Mol. Biol. Cell. 11:27752791.
Garbern, J., F. Cambi, M. Shy, and J. Kamholz. 1999. The molecular pathogenesis of Pelizaeus-Merzbacher disease. Arch. Neurol. 56:12101214.
Gow, A., and R.A. Lazzarini. 1996. A cellular mechanism governing the severity of Pelizaeus-Merzbacher disease. Nat. Genet. 13:422428.[CrossRef][Medline]
Gow, A., V.L. Friedrich, Jr., and R.A. Lazzarini. 1994. Intracellular transport and sorting of the oligodendrocyte transmembrane proteolipid protein. J. Neurosci. Res. 37:563573.[CrossRef][Medline]
Gow, A., C.M. Southwood, and R.A. Lazzarini. 1998. Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease. J. Cell Biol. 140:925934.
Hodes, M.E., and S.R. Dlouhy. 1996. The proteolipid protein gene: double, double, ... and trouble. Am. J. Hum. Genet. 59:1215.[Medline]
Hornick, C.A., D.Y. Hui, and J.G. DeLamatre. 1997. A role for retrosomes in intracellular cholesterol transport from endosomes to the plasma membrane. Am. J. Physiol. 273:C1075C1081.
Inoue, Y., T. Kagawa, Y. Matsumura, K. Ikenaka, and K. Mikoshiba. 1996. Cell death of oligodendrocytes or demyelination induced by overexpression of proteolipid protein depending on expressed gene dosage. Neurosci. Res. 25:161172.[Medline]
Jung, M., E. Krämer, M. Grzenkowski, K. Tang, W. Blakemore, A. Aguzzi, K. Khazaie, K. Chlichlia, G. von Blakenfeld, H. Kettenmann, and J. Trotter. 1995. Lines of murine oligodendroglial precursor cells immortalized by an activated neu tyrosine kinase show distinct degrees of interaction with axons in vitro and in vivo. Eur. J. Neurosci. 7:12451265.[CrossRef][Medline]
Kagawa, T., K. Ikenaka, Y. Inoue, S. Kuriyama, T. Tsujii, J. Nakao, K. Nakajima, J. Aruga, H. Okano, and K. Mikoshiba. 1994. Glial cell degeneration and hypomyelination caused by overexpression of myelin proteolipid protein gene. Neuron. 13:427442.[CrossRef][Medline]
Kalway, S.A., R. Smith, and G.J. Kidd. 1997. Myelin proteolipid protein expressed in COS-1 cells is targeted to actin-associated surfaces. J. Neurosci. Res. 48:201211.[CrossRef][Medline]
Keller, P., and K. Simons. 1998. Cholesterol is required for surface transport of influenza virus hemagglutinin. J. Cell Biol. 140:13571367.
Keller, P., D. Toomre, E. Diaz, J. White, and K. Simons. 2001. Multicolour imaging of post-Golgi sorting and trafficking in live cells. Nat. Cell Biol. 3:140149.[CrossRef][Medline]
Kim, T., K. Fiedler, D.L. Madison, W.H. Krueger, and S.E. Pfeiffer. 1995. Cloning and characterization of MVP17: a developmentally regulated myelin protein in oligodendrocytes. J. Neurosci. Res. 42:413422.[CrossRef][Medline]
Klugmann, M., M.H. Schwab, A. Puhlhofer, A. Schneider, F. Zimmermann, I.R. Griffiths, and K.-A. Nave. 1997. Assembly of CNS myelin in the absence of proteolipid protein. Neuron. 18:5970.[CrossRef][Medline]
Kobayashi, T., E. Stang, K.S. Fang, P. den Moerloose, R.G. Parton, and J. Gruenberg. 1998. A lipid associated with the antiphosphospholipid syndrome regulates endosome structure and function. Nature. 392:193197.[CrossRef][Medline]
Kobayashi, T., M.-H. Beuchat, M. Lindsay, S. Frias, R.D. Palmiter, H. Skuraba, R.G. Parton, and J. Gruenberg. 1999. Late endosomal membranes rich in lysobisphosphatidic acid regulate cholesterol transport. Nat. Cell Biol. 1:113118.[CrossRef][Medline]
Kobayashi, T., A. Yamji-Hasegawa, and E. Kiyokawa. 2001. Lipid domains in the endocytic pathway. Semin. Cell Dev. Biol. 12:173182.[CrossRef][Medline]
Krämer, E.-M., T. Koch, A. Niehaus, and J. Trotter. 1997. Oligodendrocytes direct glucosylphosphatidylinositol-anchored proteins to the myelin sheath in glycosphingolipid-rich complexes. J. Biol. Chem. 272:89378945.
Krämer, E.-M., A. Schardt, and K.-A. Nave. 2001. Membrane traffic in myelinating oligodendrocytes. Microsc. Res. Tech. 52:656671.[CrossRef][Medline]
Liljeström, P., and H. Garoff. 1991. A new generation of animal cell expression vectors based on the Semliki forest virus replication. Biotechnology (NY). 9:13561361.
Linington, C., and T.V. Waehneldt. 1990. Conservation of the carboxyl terminal epitope of myelin proteolipid protein in the tetrapods and lobe-finned fish. J. Neurochem. 54:13541359.[CrossRef][Medline]
Liscum, L. 2000. Niemann-Pick type C mutations cause lipid traffic jam. Traffic. 1:218225.[CrossRef][Medline]
Lusa, S., T.S. Blom, E.-L. Eskelinen, E. Kuismanen, J.-E. Mansson, K. Simons, and E. Ikonen. 2001. Depletion of rafts in late endocytic membrane is controlled by NPC1-dependent recycling of cholesterol to the plasma membrane. J. Cell Sci. 114:18931900.[Abstract]
Macklin, W.B., B.D. Trapp, T. Kagawa, and K. Ikenaka. 1995. Hypomyelination in transgenic mice with multiple copies of the myelin proteolipid protein gene. J. Neurochem. 64:S86.
Martin, O.C., and R.E. Pagano. 1994. Internalization and sorting of a fluorescent analog of glucosylceramide to the Golgi apparatus of human skin fibroblasts: utilization of endocytic and nonendocytic transport mechanism. J. Cell Biol. 125:769781.
Mukherjee, S., X. Zha, I. Tabas, and F.R. Maxfield. 1998. Cholesterol distribution in living cells: fluorescence imaging using dehydroergosterol as a fluorescent cholesterol analog. Biophys. J. 75:19151925.
Nichols, A.J., A.K. Kenworthy, R.S. Polishchuk, R. Lodge, T.H. Roberts, K. Hirschberg, R.D. Phair, and J. Lippincott-Schwartz. 2001. Rapid recycling of lipid raft markers between the cell surface and Golgi complex. J. Cell Biol. 153:529541.
Osterhout, D.J., A. Wolven, R.M. Wolf, M.D. Resh, and M.V. Chao. 1999. Morphological differentiation of oligodendrocytes requires activation of fyn tyrosine kinase. J. Cell Biol. 145:12091218.
Pentchev, P.G., M.T. Vanier, K. Suzuki, and M. Patterson. 1995. Niemann-Pick disease type C: a cellular cholesterol lipidosis. The Metabolic and Molecular Bases of Inherited Disease. C.R. Scriver, W.S. Beudet and D. Sly, editors. McGraw-Hill, New York. 26252639.
Pereyra, P.M., E. Horvath, and P.E. Braun. 1988. Triton X-100 extractions of central nervous system myelin indicate a possible role for the minor myelin proteins in stability of lamellae. Neurochem. Res. 13:583595.[CrossRef][Medline]
Pfeiffer, S.E., A.E. Warrington, and R. Bansal. 1993. The oligodendrocyte and its many cellular processes. Trends Cell Biol. 3:191197.[CrossRef][Medline]
Puri, V., R. Watanabe, M. Dominguez, X. Sun, C.L. Wheatley, D.L. Marks, and R.E. Pagano. 1999. Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases. Nat. Cell Biol. 1:386388.[CrossRef][Medline]
Readhead, C., A. Schneider, I. Griffiths, and K.-A. Nave. 1994. Premature arrest of myelin formation in transgenic mice with increased proteolipid protein gene dosage. Neuron. 12:583595.[CrossRef][Medline]
Simons, K., and J. Gruenberg. 2000. Jamming the endosomal system: lipid rafts and lysosomal storage disease. Trends Cell Biol. 10:459462.[CrossRef][Medline]
Simons, K., and E. Ikonen. 1997. Functional rafts in cell membranes. Nature. 387:569572.[CrossRef][Medline]
Simons, M., E.-M. Krämer, C. Thiele, W. Stoffel, and J. Trotter. 2000. Assembly of myelin by association of proteolipid protein with cholesterol- and galactosylceramide-rich membrane domains. J. Cell Biol. 151:143153.
Simonsen, A., R. Lippe, S. Christoforidis, J.M. Gaullier, A. Brech, J. Callaghan, B.H. Toh, C. Murphy, M. Zerial, and H. Stenmark. 1998. EEA1 links PI(3)K function to Rab5 regulation of endosome fusion. Nature. 394:494498.[CrossRef][Medline]
Sinoway, M.P., K. Kitagawa, S. Timsit, G.A. Hashim, and D.R. Colman. 1994. Proteolipid protein interactions in transfectants: implications for myelin assembly. J. Neurosci. Res. 37:551562.[CrossRef][Medline]
Sperber, B.R., E.A. Boyle-Walsh, M.J. Engleka, P. Gadue, A.C. Peterson, P.L. Stein, S.S. Scherer, and F.A. McMorris. 2001. A unique role for fyn in CNS myelination. J. Neurosci. 21:20392047.
Suter, U., and G.J. Snipes. 1995. Biology and genetics of hereditary motor and sensory neuropathies. Annu. Rev. Neurosci. 18:4575.[CrossRef][Medline]
Umemori, H., S. Sato, T. Yagi, S. Alzawa, and T. Yamamoto. 1994. Initial events of myelination involve fyn tyrosine kinase signalling. Nature. 367:572576.[CrossRef][Medline]
van der Haar, M.E., H.W. Visser, H. de Vries, and D. Hoekstra. 1998. Transport of proteolipid protein to the plasma membrane does not depend on glycosphingolipid cotransport in oligodendrocyte cultures. J. Neurosci. Res. 51:371381.[CrossRef][Medline]
Viola, A. 2001. The amplification of TCR signaling by dynamic membrane microdomains. Trends Immunol. 22:322327.[CrossRef][Medline]
Weimbs, T., and W. Stoffel. 1992. Proteolipid protein (PLP) of CNS myelin: position of free, disulfide-bonded, and fatty acid thioester-linked cysteine residues and implication for the membrane topology of PLP. Biochemistry. 31:1228912296.[CrossRef][Medline]
Related Article
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|